ARTV

Artiva Biotherapeutics, Inc. Common Stock

2.39 USD
-0.06
2.45%
At close Apr 30, 4:00 PM EDT
After hours
2.46
+0.07
2.93%
1 day
-2.45%
5 days
-3.63%
1 month
-20.33%
3 months
-55.74%
6 months
-76.45%
Year to date
-76.03%
1 year
-80.08%
5 years
-80.08%
10 years
-80.08%
 

About: Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).

Employees: 89

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

200% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 6

19% more funds holding

Funds holding: 48 [Q3] → 57 (+9) [Q4]

1.9% more ownership

Funds ownership: 85.22% [Q3] → 87.12% (+1.9%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]

33% less capital invested

Capital invested by funds: $319M [Q3] → $213M (-$106M) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$18
653%
upside
Avg. target
$20
747%
upside
High target
$23
862%
upside

4 analyst ratings

positive
100%
neutral
0%
negative
0%
Needham
Gil Blum
18% 1-year accuracy
29 / 158 met price target
862%upside
$23
Buy
Reiterated
8 Apr 2025
HC Wainwright & Co.
Edward White
22% 1-year accuracy
32 / 148 met price target
737%upside
$20
Buy
Reiterated
26 Mar 2025
Wedbush
Martin Fan
50% 1-year accuracy
1 / 2 met price target
653%upside
$18
Outperform
Reiterated
25 Mar 2025
Cantor Fitzgerald
Josh Schimmer
25% 1-year accuracy
14 / 55 met price target
737%upside
$20
Overweight
Maintained
25 Mar 2025

Financial journalist opinion

Neutral
GlobeNewsWire
2 days ago
Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting
Prolonged duration of response, deep B-cell depletion, and well-tolerated safety profile support the potential of AlloNK® + rituximab for the treatment of B-cell driven diseases in a community setting
Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting
Neutral
GlobeNewsWire
3 weeks ago
Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer
Dr. Banerjee's appointment culminates Artiva's efforts to build a seasoned development team with strong expertise in autoimmune diseases and cell therapy Dr. Banerjee's appointment culminates Artiva's efforts to build a seasoned development team with strong expertise in autoimmune diseases and cell therapy
Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer
Neutral
GlobeNewsWire
1 month ago
Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that management will present at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025, at 11:00 a.m. EDT.
Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
Neutral
GlobeNewsWire
1 month ago
Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights
Initial data for AlloNK® from autoimmune program expected H1 2025 Updated clinical data from Phase 1/2 trial exploring AlloNK + rituximab in NHL showing continued durability of response to be presented at a medical conference in 2025 Strengthened key leadership with cell therapy and autoimmune expertise across organization Robust balance sheet with cash, cash equivalents and investments of $185.4 million as of December 31, 2024, is expected to fund operations at least through end of 2026 SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced financial results for the full year ended December 31, 2024, and highlighted recent progress. “2024 was a transformational year for Artiva including initiating dosing of AlloNK® in patients with autoimmune disease across our trials, a successful initial public offering strengthening our balance sheet, and expanding key leadership across the organization with expertise in cell therapy and autoimmune disease,” said Fred Aslan, M.D.
Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights
Neutral
GlobeNewsWire
2 months ago
Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that management will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025, at 2:30 p.m. EST, in Boston, MA.
Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
Neutral
GlobeNewsWire
3 months ago
Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D.
SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Dan Baker, M.D., as an independent member of its Board of Directors. Dr. Baker brings over two decades of drug development experience in the pharmaceutical industry. He is currently the interim Chief Development Officer of Cue Biopharma, Inc., and previously held a 19-year tenure at Johnson & Johnson (Janssen/Centocor) (J & J) most recently as the Vice President of Immunology R&D.
Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D.
Neutral
GlobeNewsWire
5 months ago
Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Expanded Board of Directors with appointment of Dr. Alison Moore bringing cell therapy and manufacturing expertise to advance AlloNK® in autoimmune diseases
Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Neutral
GlobeNewsWire
5 months ago
Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference
SAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 3:30 p.m. GMT, in London, UK.
Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference
Neutral
GlobeNewsWire
6 months ago
Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors
SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Alison Moore, Ph.D., as an independent member of its Board of Directors.
Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors
Neutral
GlobeNewsWire
7 months ago
Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference
SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that management will participate in a fireside chat at the 2024 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 18, 2024, at 8:00 a.m.
Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference
Charts implemented using Lightweight Charts™